TL;DR
Gene therapy targeting mecciRNAs and mt-dsRNAs combined with mitochondrial delivery represents a promising strategy for HF treatment.
This review examines mitochondrial pathology as the central orchestrator of SIC progression and integrates mitochondrial biology, immunometabolism, and translational medicine to identify promising directions for improving patient outcomes.
This review discusses the biochemical links between oxidative stress and mitochondrial dysfunction and their roles in cardiovascular disease, type 2 diabetes, neurodegeneration, metabolic liver disease, cancer, and aging, and widely used biomarkers and current therapeutic strategies.
This Review summarizes mitochondrial pathological mechanisms in neurodegenerative diseases and discusses emerging mitochondria-targeted therapeutic strategies, highlighting delivery technologies, therapeutic modalities, and translational challenges.
This review emphasizes not only mechanistic advances but also conflicting findings, model limitations, and the barriers that currently separate experimental efficacy from clinically meaningful CKD outcomes.
This review systematically summarizes the mechanisms of MQC dysregulation in metabolic diseases, the evidence supporting natural small-molecule interventions, and strategies for formulation and delivery optimization.
The aim is to balance the antitumor efficacy of DOX and reduce its cardiac adverse effects, thereby providing a new theoretical basis and potential therapeutic targets for the clinical prevention and treatment of DIC.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
